4-HO-DET: Difference between revisions

>Unity
>Unity
No edit summary
Line 5: Line 5:
| ''[[4-HO-DET/Summary|Summary sheet: 4-HO-DET]]''
| ''[[4-HO-DET/Summary|Summary sheet: 4-HO-DET]]''
|}
|}
'''N,N-Diethyl-4-hydroxytryptamine'''  (abbreviated '''4-HO-DET'''; also known as '''4-hydroxy-N,N-diethyltryptamine''', '''CZ-74''', or '''Ethocin''') is a synthetic [[psychoactive class::psychedelic]] [[chemical class::tryptamine]] that is a close structural and functional analog of [[psilocin]] (4-HO-DMT), the principal psychoactive substance in [[magic mushrooms]] and shares many but not all its core features.
'''N,N-Diethyl-4-hydroxytryptamine'''  (abbreviated '''4-HO-DET'''; also known as '''4-hydroxy-N,N-diethyltryptamine''', '''CZ-74''', or '''Ethocin''') is a synthetic [[psychoactive class::psychedelic]] [[chemical class::tryptamine]] that is a close structural and functional analog of [[psilocin]] (4-HO-DMT), the principal psychoactive substance in [[magic mushrooms]]. It is notable for sharing many but of its core features while retaining variations in style and effects.


This compound was first discovered in the late 1950s by [[Albert Hofmann]] (famed inventor/discoverer of [[LSD]]) and Franz Troxler.<ref>Therapeutic indoles for psychic stimulation and relief of mental depression | http://www.google.com/patents/US3072530</ref><ref>United States Patent Office | https://www.erowid.org/archive/rhodium/pdf/psilocin.esters.pdf</ref> The substance was used together with its phosphoryloxy-analog [[4-PO-DET]] in human clinical trials in the 1960s by the German researchers Hanscarl Leuner and G. Baer.
This compound was first discovered in the late 1950s by [[Albert Hofmann]] (famed inventor/discoverer of [[LSD]]) and Franz Troxler.<ref>Therapeutic indoles for psychic stimulation and relief of mental depression | http://www.google.com/patents/US3072530</ref><ref>United States Patent Office | https://www.erowid.org/archive/rhodium/pdf/psilocin.esters.pdf</ref> The substance was used together with its phosphoryloxy-analog [[4-PO-DET]] in human clinical trials in the 1960s by the German researchers Hanscarl Leuner and G. Baer.